Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …

Mesenchymal stromal cells (MSCs) are a subset of heterogeneous non-hematopoietic
fibroblast-like cells that can differentiate into cells of multiple lineages, such as …

Objective This paper describes the University of Michigan's nine-year experience in
developing and using a full-text search engine designed to facilitate information retrieval (IR) …

For over 60 years, hematopoietic stem cell transplantation has been the major curative
therapy for several hematological and genetic disorders, but its efficacy is limited by the …

BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or
severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) …

Background No plasma biomarkers are associated with the response of acute graft-versus-
host disease (GVHD) to therapy after allogeneic hematopoietic stem-cell transplantation …

Tumor necrosis factor α (TNF) is a potent pro-inflammatory cytokine that has deleterious
effect in some autoimmune diseases, which led to the use of anti-TNF drugs in some of …

Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid
immunosuppression. Clinical response after 1 week of therapy often guides further treatment …

Background Graft-versus-host disease (GVHD) is the major cause of non-relapse mortality
after allogeneic haemopoietic stem-cell transplantation (SCT). The severity of symptoms at …

The limiting factor for successful hematopoietic stem cell transplantation (HSCT) is graft-
versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated …